Mollica, V.; Nuvola, G.; Tassinari, E.; Nigro, M.C.; Marchetti, A.; Rosellini, M.; Rizzo, A.; Errani, C.; Massari, F.
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. Curr. Oncol. 2022, 29, 1709-1722.
https://doi.org/10.3390/curroncol29030142
AMA Style
Mollica V, Nuvola G, Tassinari E, Nigro MC, Marchetti A, Rosellini M, Rizzo A, Errani C, Massari F.
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. Current Oncology. 2022; 29(3):1709-1722.
https://doi.org/10.3390/curroncol29030142
Chicago/Turabian Style
Mollica, Veronica, Giacomo Nuvola, Elisa Tassinari, Maria Concetta Nigro, Andrea Marchetti, Matteo Rosellini, Alessandro Rizzo, Costantino Errani, and Francesco Massari.
2022. "Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw" Current Oncology 29, no. 3: 1709-1722.
https://doi.org/10.3390/curroncol29030142
APA Style
Mollica, V., Nuvola, G., Tassinari, E., Nigro, M. C., Marchetti, A., Rosellini, M., Rizzo, A., Errani, C., & Massari, F.
(2022). Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. Current Oncology, 29(3), 1709-1722.
https://doi.org/10.3390/curroncol29030142